<DOC>
	<DOCNO>NCT01106469</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability , food effect well pharmacokinetics ( drug absorb body , distribute within body remove body time ) pharmacodynamics ( effect drug ) single multiple ascend dos JNJ-41443532 healthy male participant .</brief_summary>
	<brief_title>Pharmacokinetics ( PK ) Pharmacodynamics ( PD ) Study Single Multiple Ascending Doses JNJ-41443532 Healthy Male Participants</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , double-blind ( neither physician participant know name assigned drug ) , placebo-controlled , single multiple ascend dose study conduct single study center . The study 4 part . Part 1 randomize , double-blind , alternating panel , single ascend oral dose study . Two alternate treatment panel ( A B ) nine healthy male participant study successively increase dose level . Part 2 randomized , open-label ( people involve know identity intervention ) , 2-period crossover study evaluate effect administer JNJ- 41443532 food ( i.e . standard high fat breakfast meal ) relative administration fast state pharmacokinetics/blood level JNJ-41443532 . Part 3 randomize , double-blind , single oral dose study obese , otherwise healthy male participant . Part 4 double-blind , randomize , placebo-controlled multiple ascend dose study 5 sequential treatment group healthy male participant . Safety assessment include monitor adverse event , evaluation lab result , cardiac parameter , vital sign , physical exam . In Parts 1 , 2 , 3 participant receive study medication ( JNJ-41443532 placebo ) orally Day 1 overnight fast least 10 hour ; plan dose 25 1500 mg . In Part 4 , participant receive study medication ( JNJ-41443532 placebo ) orally day 10 consecutive day overnight fast least 10 hour ; plan dose 100 1000 mg .</detailed_description>
	<criteria>Males , age 18 45 year inclusive Part 1 age 18 55 year inclusive Parts 2 , 3 , 4 Weight = 60 kilogram Body Mass Index ( BMI ) 18.5 29.9 kg/m2 ( inclusive ) BMI 30 39.9 kg/m2 obese participant Healthy basis physical examination , medical history , vital sign , electrocardiogram ( ECG ) , clinical laboratory test perform screen Men must agree use double barrier method birth control ( e.g . condom use spermicide diaphragm , hormonal contraceptive intrauterine device female partner ) donate sperm study 3 month receive last dose study drug Willing adhere prohibition restriction specify protocol History , currently active , significant illness medical disorder , include ( limited ) cardiovascular disease ( include cardiac arrhythmia , myocardial infarction , stroke , peripheral vascular disease ) , endocrine metabolic disease ( e.g . hyper/hypothyroidism ) , hematological disease ( e.g . von Willebrand 's disease bleeding disorder ) , respiratory disease , hepatic gastrointestinal disease , neurological psychiatric disease , ophthalmologic disorder ( include retinal disorder cataract ) , neoplastic disease , skin disorder , illness Investigator considers exclude participant Participants risk QTc prolongation ( specific heart rhythm irregularity ) Within 12 month prior screen , clinically important , serious infection ( e.g . hepatitis , pneumonia , pyelonephritis ) , hospitalize infection treat intravenous ( IV ) antibiotic infection Smoker tobacco user within past 3 month History alcohol drug abuse History clinically significant drug and/or food allergy , include allergy intolerance ( e.g . lactose intolerance ) Donation 1 unit blood acute loss equivalent amount blood within 60 day prior study drug administration Received experimental drug use experimental medical device within 60 day</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Healthy</keyword>
	<keyword>JNJ-41443532</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>